Landos Biopharma, Inc.: insider trades · United States · SEC (Form 4)

About Landos Biopharma, Inc.

Landos Biopharma, Inc. is a U.S.-based biopharmaceutical company listed on NASDAQ in the United States, operating in the highly specialized autoimmune and inflammatory disease space. The company was historically headquartered in Blacksburg, Virginia, and was built around its proprietary LANCE® platform, an AI-enabled discovery engine designed to identify novel oral therapeutics against differentiated biological targets. Landos’ business model was that of a clinical-stage biotech: enterprise value depended primarily on pipeline advancement, clinical data generation, and regulatory interaction with the FDA rather than on commercial product sales. At the core of the company’s strategy was the development of oral treatments for patients with autoimmune disorders. Its best-known programs included omilancor, LABP-104, LABP-111, and NX-13, a candidate evaluated in ulcerative colitis. This pipeline reflected a focus on gut-restricted or systemically active small molecules with the potential to offer an oral alternative to biologic therapies. From an investor perspective, that positioning could have been attractive if the clinical profile showed meaningful efficacy, safety, and differentiation versus established standards of care. Landos competed in a crowded and capital-intensive environment dominated by large pharmaceutical companies and a wide set of immunology and gastroenterology specialists. Its competitive edge was not scale, but scientific specialization, intellectual property, and the ability to generate compelling clinical proof points. In other words, this was a catalyst-driven biotech story rather than a mature healthcare franchise. Geographically, Landos’ operations were centered in the United States, with a historical base in Blacksburg, Virginia, and its equity market visibility tied to NASDAQ. Public disclosures and regulatory activity were U.S.-centric, which is typical for a development-stage biotech with domestic clinical and corporate infrastructure. The most important recent milestone came in March 2024, when Landos announced a definitive agreement to be acquired by AbbVie. That announcement materially changed the company’s strategic and valuation framework, shifting the investment case from standalone pipeline execution toward acquisition completion and transaction risk. In addition, the SEC Form 4 filings associated with LABP provide ongoing transparency into insider ownership changes, a relevant point for governance and insider-activity analysis. Overall, Landos Biopharma should be viewed as a U.S. NASDAQ-listed biotech whose story has been defined by autoimmune pipeline development, oral small-molecule innovation, and, more recently, a takeover process that re-shaped the company’s market position.